You are here: Industry Insights > BioPharmX

News List

BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 americanpharmaceuticalreview
June 26, 2019
BioPharmX announced positive results from its Phase 2b clinical trial of BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea.
BioPharmX Announces Patent Award americanpharmaceuticalreview
August 10, 2018
BioPharmX announced the U.S. Patent and Trademark Office has granted a fifth patent to the company.
U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Top biospace
March 21, 2018
BioPharmX Corporation announced today that the U.S. Patent and Trademark Office granted the company's first patent
BioPharmX Receives Concurrence from FDA on Phase 3 Acne Study Plans americanpharmaceuticacreview
November 09, 2017
Consistent with oral minocycline products, BPX-01 is intended for the targeted treatment of non-nodular inflammatory acne vulgaris.
BioPharmX Invited to Present at World Preclinical Congress biospectrumasia
June 19, 2017
The company presented results of a three arm preclinical study comparing BPX-01 topical hydrophilic formulation of minocycline, lipophilic minocycline formulation and oral minocyline.